PL3459933T3 - Stałe postacie farmaceutycznie czynnego związku - Google Patents

Stałe postacie farmaceutycznie czynnego związku

Info

Publication number
PL3459933T3
PL3459933T3 PL18200578.5T PL18200578T PL3459933T3 PL 3459933 T3 PL3459933 T3 PL 3459933T3 PL 18200578 T PL18200578 T PL 18200578T PL 3459933 T3 PL3459933 T3 PL 3459933T3
Authority
PL
Poland
Prior art keywords
active compound
pharmaceutically active
solid forms
solid
forms
Prior art date
Application number
PL18200578.5T
Other languages
English (en)
Inventor
Rudolf Benz
Ralph Diodone
Zhongjiang JIA
Bharat Patel
Urs Schwitter
Duk Soon Choi
Ningxin YAN
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Publication of PL3459933T3 publication Critical patent/PL3459933T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PL18200578.5T 2014-04-15 2015-04-13 Stałe postacie farmaceutycznie czynnego związku PL3459933T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461979649P 2014-04-15 2014-04-15

Publications (1)

Publication Number Publication Date
PL3459933T3 true PL3459933T3 (pl) 2023-01-23

Family

ID=52815005

Family Applications (1)

Application Number Title Priority Date Filing Date
PL18200578.5T PL3459933T3 (pl) 2014-04-15 2015-04-13 Stałe postacie farmaceutycznie czynnego związku

Country Status (18)

Country Link
US (1) US10227298B2 (pl)
EP (2) EP3459933B1 (pl)
JP (2) JP6621761B2 (pl)
KR (1) KR20160138307A (pl)
CN (1) CN106458886A (pl)
AR (1) AR100095A1 (pl)
AU (1) AU2015249018A1 (pl)
BR (1) BR112016023767A2 (pl)
CA (1) CA2943571A1 (pl)
ES (1) ES2928706T3 (pl)
IL (1) IL247974A0 (pl)
MA (1) MA39877A (pl)
MX (1) MX2016013439A (pl)
PL (1) PL3459933T3 (pl)
RU (1) RU2016144187A (pl)
SG (1) SG11201608559QA (pl)
WO (1) WO2015158648A1 (pl)
ZA (1) ZA201606653B (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109152843A (zh) 2016-05-20 2019-01-04 豪夫迈·罗氏有限公司 Protac抗体缀合物及其使用方法
WO2019213106A1 (en) 2018-04-30 2019-11-07 Teva Pharmaceuticals International Gmbh Solid state forms of idasanutlin
WO2022183006A1 (en) 2021-02-25 2022-09-01 Mayo Foundation For Medical Education And Research Compounds for programmable protein degradation and methods of use for the disease treatment
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same
WO2024240858A1 (en) 2023-05-23 2024-11-28 Valerio Therapeutics Protac molecules directed against dna damage repair system and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8354444B2 (en) * 2008-09-18 2013-01-15 Hoffmann-La Roche Inc. Substituted pyrrolidine-2-carboxamides
US8993614B2 (en) * 2012-03-15 2015-03-31 F. Hoffmann-La Roche Ag Substituted pyrrolidine-2-carboxamides
US9216170B2 (en) * 2012-03-19 2015-12-22 Hoffmann-La Roche Inc. Combination therapy for proliferative disorders
US20130245089A1 (en) 2012-03-19 2013-09-19 Hoffmann-La Roche Inc. Method for administration
CN107540594A (zh) * 2012-05-30 2018-01-05 霍夫曼-拉罗奇有限公司 取代的吡咯烷‑2‑甲酰胺
NZ708272A (en) * 2013-01-22 2020-07-31 Hoffmann La Roche Pharmaceutical composition with improved bioavailability
RU2015133939A (ru) 2013-02-21 2017-03-27 Ф. Хоффманн-Ля Рош Аг Асимметрический синтез замещенного пирролидин-2-карбоксамида

Also Published As

Publication number Publication date
RU2016144187A3 (pl) 2018-11-13
ES2928706T3 (es) 2022-11-22
JP6887980B2 (ja) 2021-06-16
WO2015158648A1 (en) 2015-10-22
AR100095A1 (es) 2016-09-07
SG11201608559QA (en) 2016-11-29
EP3131878A1 (en) 2017-02-22
US10227298B2 (en) 2019-03-12
US20170037005A1 (en) 2017-02-09
JP2017511362A (ja) 2017-04-20
JP6621761B2 (ja) 2019-12-18
AU2015249018A1 (en) 2016-10-06
KR20160138307A (ko) 2016-12-02
CA2943571A1 (en) 2015-10-22
EP3459933A3 (en) 2019-05-29
JP2019055960A (ja) 2019-04-11
EP3459933A2 (en) 2019-03-27
CN106458886A (zh) 2017-02-22
MA39877A (fr) 2017-02-22
ZA201606653B (en) 2018-05-30
EP3459933B1 (en) 2022-08-24
IL247974A0 (en) 2016-11-30
RU2016144187A (ru) 2018-05-16
MX2016013439A (es) 2016-11-17
BR112016023767A2 (pt) 2017-08-15

Similar Documents

Publication Publication Date Title
GB201419579D0 (en) Pharmaceutical compound
GB201414730D0 (en) Pharmaceutical compound
GB201511790D0 (en) Pharmaceutical compound
SMT202100444T1 (it) Composizioni farmaceutiche di composti terapeuticamente attivi
IL281292B1 (en) Processes for preparing a diarylthiohydantoin compound
ZA201700022B (en) A novel formulation of meloxicam
GB201516411D0 (en) Pharmaceutical compound
LT3226888T (lt) Selektyvaus il-6-trans-signalinio inhibitoriaus skyrimas
ZA201606653B (en) Solid forms of a pharmaceutically active compound
ZA201700518B (en) Use of active compound compositions
SG11201708818VA (en) Pharmaceutical compound
ZA201607256B (en) Active compound combinations
SG11201708817XA (en) Pharmaceutical compound
GB201508787D0 (en) Pharmaceutically active compounds
GB201519919D0 (en) Pharmaceutically active compounds
GB201403538D0 (en) Pharmacologically active compounds
GB201518603D0 (en) Therapeutically active compounds
TWM490349U (en) Improved structure of a darter
GB201419570D0 (en) Pharmaceutical compound
GB201411215D0 (en) Pharmaceutical compound
GB201406154D0 (en) Pharmaceutical compound
GB201402341D0 (en) Pharmaceutical compound
GB201507883D0 (en) Pharmaceutical compound
GB201502156D0 (en) Pharmaceutical compound